Project Grant HT94252510226
Award Date
4/15/25
Completion Date
4/14/28
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Ames, IA 50011, USA
Similar Awards
This federal Project Grant award of $3,560,880.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the public. The primary awardee, the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will conduct specialized research projects across diverse medical domains, including cancer prevention,...
The University of Iowa received a $816,178 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "TARGETED THERAPY FOR MPNST METASTASIS," will support research activities at the University of Iowa from June 1, 2024 to May 31, 2027. The research aims to develop innovative treatments for metastatic malignant peripheral nerve sheath tumors, a rare and aggressive type of cancer. This federal grant...
This $155,500 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research conducted by the University of Iowa to investigate a targeted approach of NRF2 inhibition in neuroendocrine cancers. The award period runs from November 1, 2024 to October 31, 2026. The University of Iowa, a major public research university, will leverage its expertise in areas such as medicine, engineering, and healthcare to deliver...
The federal Project Grant award of $254,153.00 was made on March 1, 2025 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports advanced biomedical research focused on the relationship between microplastics and prostate cancer at New York University School of Medicine, a prominent academic medical center and research institution. The funding will enable researchers to investigate innovative approaches to disease prevention,...
This federal Project Grant award, valued at $1,235,845.00, was provided by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Illinois to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The grant, with a performance period from August 15, 2025 to August 14, 2028, supports advanced biomedical research initiatives focused on transforming healthcare for military service...
The University of Iowa was awarded a $1,529,022 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year award will fund research from February 2021 to February 2024 to investigate SUMO inhibition and its ability to repress mammary oncogenesis through the ETV1 protein. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $516,366 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. The 3-year award to the University of Wisconsin System, with a performance period from September 1, 2024 to August 31, 2027, will fund innovative approaches to advance the treatment and management of prostate cancer, a significant health...
The Department of the Army Medical Command awarded Duke University a $472,184 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2024 to exploit ferropotosis for the treatment of RB1-deficient lethal prostate cancer. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and public health care...
This federal Project Grant award, valued at $785,833.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research targeting immunotherapy-resistant lesions to eradicate oligometastatic prostate cancer, with a performance period from September 1, 2024 to August 31, 2027. The primary awardee is the University of Wisconsin System, specifically the University of Wisconsin-Madison's Research and Sponsored Programs...
The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...